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Abstract
Because passage of the bacterium to blood is a crucial step in the pathogenesis of many group B Streptococcus (GBS)
invasive infections, we recently conducted a whole-genome transcriptome analysis during GBS incubation ex vivo with
human blood. In the current work, we sought to analyze in detail the difference in GBS gene expression that occurred in one
blood sample (donor A) relative to other blood samples. We incubated GBS strain NEM316 with fresh heparinized human
blood obtained from healthy volunteers, and analyzed GBS genome expression and cytokine production. Principal
component analysis identified extensive clustering of the transcriptome data among all samples at time 0. In striking
contrast, the whole bacterial gene expression in the donor A blood sample was significantly different from the gene
expression in all other blood samples studied, both after 30 and 90 min of incubation. More genes were up-regulated in
donor A blood relative to the other samples, at 30 min and 90 min. Furthermore, there was significant variation in transcript
levels between donor A blood and other blood samples. Notably, genes with the highest transcript levels in donor A blood
were those involved in carbohydrate metabolism. We also discovered an unusual production of proinflammatory and
immunomodulatory cytokines: MIF, tPAI-1 and IL-1b were produced at higher levels in donor A blood relative to the other
blood samples, whereas GM-CSF, TNF-a, IFN-c, IL-7 and IL-10 remained at lower levels in donor A blood. Potential reasons
for our observations are that the immune response of donor A significantly influenced the bacterial transcriptome, or both
GBS gene expression and immune response were influenced by the metabolic status of donor A.
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Introduction
Streptococcus agalactiae (group B Streptococcus, GBS) is a common
inhabitant of the human gut and genitourinary tract, and also
rarely colonizes other anatomic sites [1]. GBS is also the major
cause of neonatal infections, with an estimated incidence of ,34
cases per 100,000 live births in the United States [2]. For several
years, phylogenetic analyses have identified high-risk lineages,
grouping strains more frequently implicated in neonatal diseases,
regardless of the genetic typing method used [3,4,5,6,7]. More
recently, it was also proposed that the major hyperinvasive
neonatal clone had emerged from a bovine ancestor [8],
suggesting that a greater genetic distance from other human
lineages might explain the higher invasiveness of this lineage
among neonates [9].
However, the phylogeny does not correlate as well with the
epidemiology of GBS non-pregnant adult infections, which have
drastically increased in the last two decades [10]. Conversely, GBS
predominantly infects elderly and immunocompromised patients,
highlighting the idea that underlying medical conditions increase
the risk of non-pregnant adults to develop invasive GBS infections.
For example, the most common predisposing conditions observed
in adult populations are diabetes and malignancy [10]. Indeed, it is
well-known that components of the host immune system,
especially the innate response and the polymorphonuclear
neutrophils, may be detrimentally altered in diabetic patients,
however, the exact mechanisms responsible for this are less well
characterized [11]. Similarly, immune response is decreased in
patients affected by cancer, either because of malignancy,
antineoplastic therapy, or both.
Using the serotype III strain NEM316 isolated from a patient
with fatal septicaemia [12], we recently analyzed transcriptome
changes that occur during incubation of GBS in human blood
[13], a crucial step in many invasive infections. We found that
GBS gene expression was similar during incubation in blood
obtained from seven distinct donors [13]. However, during
ongoing studies of the interaction of GBS with human blood, we
generated data suggesting that the transcriptome of strain
NEM316 was significantly different when incubated with the
blood of an eighth donor (arbitrarily referred to as donor A)
(Mereghetti unpublished data), suggesting inter-individual vari-
ability in GBS gene expression. In the present study, we sought to
analyze the differences of GBS gene expression that occurred in
this donor’s blood. We also explored human blood cytokine
response that may contribute to GBS transcriptome differences.
We found that fewer bacterial genes were down-regulated in
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in donor A blood relative to the other samples. Furthermore,
cytokine production was different in donor A blood, either before
any contact with GBS or after 90 min of incubation with this
pathogen.
Results
GBS transcriptome is different in donor A blood sample
Blood obtained from each of the eight donors was processed
separately. We found by CFU counting that there was no
significant difference in the number of input GBS inoculated into
the donor A blood sample and the seven other blood samples
(arbitrarily named donor B to H) (Fig. 1). We also documented
that there was no significant difference between the donor A blood
sample and the other blood samples in the number of viable
bacteria after 90 min of incubation in the blood (Fig. 1).
Principal component analysis (PCA) identified extensive clus-
tering of the transcriptome data among all samples at time 0,
including the donor A blood sample (Fig. 2). Conversely, the whole
bacterial gene expression in the donor A blood sample was
different from the gene expression in the seven other blood
samples, both after 30 and 90 min of incubation (Fig. 2). The
unexpected outlier position of GBS gene transcript data from
donor A blood was confirmed by a second set of microarray data
(data not shown).
Peculiar whole GBS transcriptional signature during
incubation with donor A blood
We previously showed that microarray data obtained from
seven donors were highly similar to one another [13]. Using the
microarray data obtained from these seven samples, we calculated
the average transcript level for each gene at each time point (i.e.,
immediately after mixing bacteria with donor human blood, and
after 30 and 90 min of incubation) for the 1,995 ORFs present on
the chip [13]. Differences in gene transcripts were determined by
comparing the average value from one time point to another. An
ORF was considered to be differentially expressed if there was a
‘‘present’’ signal at a minimum of one time point, if there was a
significant (P,0.05, T-test) change in expression greater than 2-
fold or lower than 0.5 at one time point relative to another, and if
these criteria were met for at least six of the seven donor samples
[13]. Similarly, we compared GBS gene expression in the donor A
blood sample after 30 and 90 min of incubation to gene expression
immediately after mixing the bacteria with the human blood. Our
analysis was based on the comparison of GBS gene expression in
the donor A blood sample and in the seven other donor blood
samples.
The expression data revealed that extensive remodelling of the
GBS transcript profile occurred during incubation of the bacterial
strain in each blood sample. Importantly, we identified a large
difference between the donor A blood sample data and data for
the other seven blood samples [13]. For example, after 30 min
incubation in donor A blood, transcripts of only 11.1% of the
ORFs present on the chip changed significantly, whereas
transcripts of 39.6% of the ORFs in the other donors’ blood were
significantly altered: 160 transcripts were up-regulated and 62
were down-regulated in donor A blood, whereas 134 transcripts
were up-regulated and 658 were down-regulated in the other
blood samples (Table 1). After 90 min incubation, 32% of the
transcripts changed in donor A blood whereas 31.7% of the
transcripts were modified in the other donors’ blood: 270
transcripts were up-regulated and 369 were down-regulated in
donor A blood, whereas 115 transcripts were up-regulated and
518 were down-regulated in the other blood samples (Table 1).
In summary, far fewer transcripts changed significantly after
30 min incubation in donor A blood relative to other blood
samples, and the changes mainly involved gene up-regulation.
Gene expression changed after 90 min incubation relative to time
0 for a similar number of genes in donor blood A and the other
blood samples, but more genes were up-regulated in donor A
blood.
Of note, the difference in gene up-regulation between donor A
and other blood samples included many genes involved in amino
acid, purine-pyrimidine, and central intermediary metabolism,
Figure 1. Number of bacterial cells during incubation with human blood. The number of CFU/ml in the donor A blood sample (marked by a
cross) is similar to the number of CFU/ml in the seven other blood samples at time 0 and after 90 min of incubation at 37uC.
doi:10.1371/journal.pone.0007145.g001
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carbohydrate metabolism (Fig. 3, and see below).
Differential levels of GBS gene expression in donor A
blood sample
To further dissect the difference of the GBS transcriptome in the
donor A blood sample relative to the other donor blood samples, we
categorized the 1,995 genes according to their level of expression.
We observed unusual features of expression of genes after 30 min of
incubation: (i) fewer genes were expressed at a very low level (or not
expressed) in the donor A blood sample than in the other blood
samples (i.e., 1,390 and 1,621 ORFs, respectively), (ii) more genes
wereexpressedat a higherlevelinthedonorA bloodsample than in
the other blood samples (i.e. 588 and 305 ORFs, respectively), and
(iii) no genes were expressed at a very high level in the donor A
blood sample to the difference of other blood samples (Fig. 4A).
Figure 2. Principal component analysis (PCA) plot showing transcriptome differences between expression microarray data of GBS
NEM316 strain incubated in human blood at 37uC. Samples were analyzed at time 0, and after 30 min and 90 min of incubation. The PCA plot
captures the variance in a dataset in terms of principal components and displays the most significant of these on the x, y, and z axes. The percentages
of the total variation that are accounted for by the 1
st,2
nd, and 3
rd principal components are shown on the x-, y- and z-axes labels. Plots are colored
and shaped by time point. Plots for donor A blood sample are specifically marked (‘‘ ’’ for time 0, ‘‘ ’’ for time 1, and ‘‘ ’’ for time 2).
doi:10.1371/journal.pone.0007145.g002
Table 1. Number (and percentage) of GBS transcripts significantly up- and down-regulated in donor A and the seven other donor
blood samples according to the duration of the incubation at 37uC.
Donor A Average 7 donors
After 30 minutes After 90 minutes After 30 minutes After 90 minutes
(time 1) (time 2) (time 1) (time 2)
Up-regulation
a 160 (72.0%) 270 (42.2%) 134 (16.9%) 115 (18.2%)
Down-regulation
a 62 (28.0%) 369 (57.8%) 658 (83.1%) 518 (81.8%)
Total
b 222 (11.1%) 639 (32.0%) 792 (39.6%) 633 (31.7%)
An ORF is considered differentially expressed if there is a significant (P,0.05, T-test) change in expression greater than 2-fold at one time point relative to another, and if
the signal is detected. Up- and down-regulation are expressed relative to time 0.
aPercentage is expressed relative to the number of genes whose expression is modified.
bPercentage is expressed relative to the total number of genes present on the chip.
doi:10.1371/journal.pone.0007145.t001
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of levels of gene expression between the donor A blood sample and
other donor blood samples after 90 min of incubation (Fig. 4B).
Difference in transcripts of genes involved in
carbohydrate metabolism
Within all functional categories of genes involved in bacterial
metabolism, the most notable difference between the data from
donor A blood and other donor blood samples was expression of
genes involved in carbohydrate metabolism. Indeed, after 30 min
of incubation, 11 and 18 ORFs related to carbohydrate
metabolism were up-regulated in donor A and the other seven
donor blood samples, respectively; after 90 min incubation, 81 and
32 ORFs were up-regulated relative to time 0 in donor A blood
and other donor blood samples, respectively. Genes encoding a
galactose PTS (gbs1920–gbs1922) and a galactose-phosphate-
isomerase (gbs1917–gbs1918) were among the highest transcripts
in donor A blood relative to the other donors’ blood (Fig. 5).
Similarly, other genes encoding proteins involved in carbohydrate
binding, transport, and metabolism were (gbs0032, gbs0033–
gbs0035, gbs1416–gbs1417, gbs1914, gbs1916) also expressed at a
higher level in donor A blood (Fig. 5 and table S1). These results
highlight a specific difference in regulation of genes involved in
carbohydrate metabolism in donor blood A relative to the other
donors, suggesting different metabolic conditions in this specific
sample and/or a putative different innate or acquired immune
response of the host.
Later expression of genes involved in stress response in
donor A blood
After 30 min of incubation, the transcripts of gbs1721
(encoding a general stress protein), gbs1202 and gbs1204
(encoding proteins belonging to the Gls24 stress family), and
gbs0808 (encoding a superoxide dismutase) were 5.8-, 2.0- and
Figure 3. Differential regulation of transcript expression in GBS strain NEM316 after incubation with human blood. Genes were
classified into 22 main functional categories. Bars indicate the numbers of genes whose expression was modified in the donor A blood sample and
the average of the seven other donor blood samples at time 1 and time 2 relative to time 0. On the left, genes that were down-regulated relative to
time 0. After 30 min of incubation, 62 transcripts were down-regulated in the donor A blood sample, while 658 transcripts were down-regulated in
the other donor blood samples. After 90 min of incubation, 369 transcripts were down-regulated in the donor A blood sample, while 518 transcripts
were down-regulated in the other donor blood samples. On the right, genes that were up-regulated relative to time 0. After 30 min of incubation,
160 transcripts were up-regulated in the donor A blood sample, while 134 transcripts were up-regulated in the other donor blood samples. After
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categorized arbitrarily as: (i) expressed at very low level or not expressed, (ii) ‘‘normally’’ expressed, and (iii) highly expressed (form left to right, first
column following five columns, and last 15 columns, respectively). After 30 min of incubation, 1,390, 588 and no ORFs were categorized as
mentioned above in donor A blood, while there were 1,621, 305 and 6 ORFs in the other blood samples. After 90 min of incubation, 1,576, 395 and no
ORFs were categorized as mentioned above in donor A blood, while there were 1,674, 294 and 6 ORFs in the other blood samples.
doi:10.1371/journal.pone.0007145.g004
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blood sample, respectively (Table S1). A similar observation was
made after 90 min of incubation. Three of these genes were also
within the most expressed ORFs in donor A blood after 90 min,
whereas there were no stress genes among the 20 most expressed
ORFs after 30 min. Taken together, these results show a lower
and later GBS stress response in donor A blood than in other
blood samples.
Complex kinetics of transcripts of proven and putative
virulence genes
After 30 min of incubation in blood, transcripts of three genes
encoding proteins with an LPXTG motif were present at higher
levels in the seven blood samples than in the donor A blood
sample: transcripts of gbs1087 (encoding the FbsA fibrinogen
binding protein), gbs2018 (encoding the BibA protein), and
gbs1420 (encoding another LPXTG motif protein) were 1.5-,
4.2- and 1.45-fold higher in the seven blood samples, respectively.
Streptococcal proteins with an LPXTG motif generally are
secreted, covalently tethered to the bacterial cell-surface, and
involved in virulence. However, after 90 min of incubation,
transcripts of gbs1087, gbs2018, and gbs1420 were higher in
donor A blood than in the other blood samples (Table S1).
Another gene putatively involved in virulence, gbs1195 (encoding
a streptokinase-like protein), was also expressed at a higher level in
the 7 blood donors after 30 min and at a higher level in donor A
blood after 90 min of incubation. Interestingly, gbs1087, gbs2018
and gbs1195 were also within the 12 highest expressed genes in
donor A blood after 90 min of incubation.
Among other proven or putative GBS virulence genes, we
observed other distinct features of the transcript kinetics. For
example, most of the genes encoding enzymes involved in
synthesis of the sialylated capsular polysaccharide (gbs1233–
gbs1247), one of the most important GBS virulence factors, and
the group B antigen (gbs1480–gbs1493), another major cell wall
polysaccharide [12], were expressed at higher levels in donor A
blood relative to the other blood samples after 30 min of
incubation. Similar kinetics were observed for gbs0456, encoding
a protein with an LPXTS motif, which was 22- and 6.6-fold more
expressed in donor A blood than in the other blood samples at
30 min and 90 min, respectively.
We also observed that after 30 min and 90 min of incubation,
gbs1053-gbs1076 were expressed from 2.2- to 18.5-fold higher in
donor A blood than in the seven other donors, and also after
90 min of incubation. Interestingly, this chromosomal region
corresponds to part of pathogenicity island IX. Although this
region of the chromosome contains mostly genes encoding
proteins of unknown function [14], it was recently shown that
genes of pathogenicity island IX were up-regulated at tempera-
tures approximating the human body compared to a lower
temperature more presentative of environmental conditions,
suggesting a role in virulence [15].
Figure 5. Differential expression of genes involved in carbohydrate metabolism in GBS strain NEM316. All of the 14 red plots mark
genes involved in carbohydrate metabolism expressed at higher levels in donor A blood (axis) relative to the other blood samples (ordinate) after
90 min incubation. For comparison, small figure on the top left represents gene expression after 30 min incubation.
doi:10.1371/journal.pone.0007145.g005
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donor A blood relative to the other blood samples
To begin to understand the significant difference between the
GBS transcriptome in donor A blood and the other donor blood
samples, we measured cytokine levels in blood immediately before
contact with GBS and after 90 min of incubation with the bacteria.
Despite inter-individual variability among blood samples, at time 0
as well as at time 2 (90 min), there was no specific difference in the
level of cytokines (for most of the cytokines tested) in donor A blood
relative to the seven other blood samples (Table S2).
However, after 90 min, IL-1b was higher in donor A blood and,
notably, MIF was 23- to 44-fold higher in donor A blood than in
the other samples, whereas there was no difference between donor
A blood and the other samples at time 0 (Fig. 6). Even though the
difference was of smaller magnitude, we also observed that at time
0 tPAI-1 in donor A blood was at the highest level (together with
donor E) relative to the other blood samples (Fig. 6). Conversely,
GM-CSF, IFN-c, IL-7, IL-10, IL-12p40, MIP-1a and MIP-1b
were present at a lower level in the donor A blood sample relative
to the other blood samples after 90 min of incubation, whereas
there was no difference between donor A blood and the other
samples at time 0 (Fig. 6). Taken together, these results show an
unexpected difference in the level of proinflammatory and
immunomodulatory cytokines in donor A blood relative to the
other blood samples. Certain cytokines were elevated predomi-
nantly after incubation with GBS, but before contact with GBS,
suggesting a physiologic state distinct to this donor relative to the
seven other subjects.
Discussion
Ex vivo studies provide important advantages in mirroring
conditions existing within infected humans [16]. A key finding
from our study is that GBS grown in the blood of donor A had an
unusual transcript pattern relative to the seven other blood donors,
both after 30 min and 90 min of incubation. The most notable
transcript differences were from genes involved in carbohydrate
metabolism. Importantly, regulation of carbohydrate metabolism
is crucial during in vitro growth and host colonization of group A
Streptococcus [17,18,19], and was recently found to be a major
feature of GBS growing in vitro in laboratory media [15].
Unexpectedly, the stress response of GBS grown in donor A blood
occurred at a later time and was of decreased magnitude. This
lead us to speculate that GBS encountered more favorable
environmental conditions in donor A blood relative to in the
other blood samples, allowing the bacterium to diversely regulate
its transcriptome according to the metabolic status or the immune
response of the host.
This latter hypothesis is based on epidemiological data showing
that GBS infections occuring in non-pregnant adults mainly affect
patients with a certain degree of immunosuppression and/or
metabolic derangements such as diabetes [2]. Thus, in addition to
the inability to accurately neutralize the infectious process, the host
immune response can conduct to variation in the expression of
virulence factors by the bacterium [20]. Indeed, some bacterial
pathogens are able to substantially modify their surface compo-
nents, as for example Borrelia burgdorferi, which changes its antigenic
expression under the influence of immune response [21]. In GBS,
hemolysin can be differentially expressed during infection in a
single patient [22,23], another phenotypic change occuring in
response to the immune response of the host, consistent with
differences in resistance to host phagocytic killing [22]. Thus, if the
immune system can exert a selective pressure on the expression of
virulence factors, it could as well influence the entire transcriptome
Figure 6. Cytokine production in the eight blood donor
samples. Cytokine concentrations were measured using the xMAP
technology combining a sandwich immunoassay with fluorescent bead-
based technology. Cytokines were measured immediately before
contact with GBS (left of each figure) and after 90 min of incubation
with the bacteria (right of each figure). tPAI-1 was higher in donor A
blood relative to the other blood samples at time 0, while MIF and IL-1b
were higher in donor A blood than in the other blood samples after
90 min. Cytokine concentrations are expressed in pg/ml.
doi:10.1371/journal.pone.0007145.g006
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genome expression in donor A blood and the other samples. It has
to be noted that there is an inter-individual variability of cytokine
production that we observed within our various samples, but such
variability has already been observed both in in vitro conditions and
during human infections [24,25]. However, our results show an
unusual immune response of the various cytokine types tested.
Indeed, production of both pro-inflammatory (such as TNF-a,
IFN-c, IL-12, and MIP) and anti-inflammatory (such as IL-10)
cytokines was significantly lower in donor A blood, whereas
conversely, another pro-inflammatory cytokine, IL-1b, was
produced at a higher level in donor A blood relative to the other
blood samples.
Another hypothesis to explain the differences in bacterial
transcriptomes between donor A blood and the other blood
samples is linked to a peculiar metabolic status of the host. This is
supported by more elevated levels of tPAI-1 and MIF in donor A
blood. A high level of tPAI-1, which is the predominant inhibitor
of the fibrinolytic system, leads to hypofibrinolysis with a lack of
dissolution of microvascular fibrin depositions as a consequence
[26]. Plasma concentration of tPAI-1 is influenced by genetic
determinants, and among metabolic determinants, by insulin
resistance and diabetes [27]. Furthermore, it has been shown that
populations who are subject to develop diabetes after several years
had higher levels of tPAI-1 than population who did not [28]. MIF
is another pro-inflammatory cytokine constitutively expressed by
various cells and tissues, and can be involved in multiple
inflammatory reactions [29]. Similarly to tPAI-1, there is strong
link between MIF production and type 2 diabetes [30], although it
is not clear yet which disorder originates the other. Thus, high
levels of both tPAI-1 and MIF might be consistent with a putative
pre-diabetic status of donor A. Interestingly, and consistent with
our results, MIF can be rapidly released from preformed pools in
response to microbial stimulation [31], and high concentrations of
MIF have been detected in the bloodstream of patients with severe
sepsis [32]. Elevated levels of tPAI-1 are also positively related to
poor outcomes and increased severity in patients suffering from
meningococcal sepsis [33].
In summary, when analyzing the GBS expression during
contact with human blood, we identified an unexpected bacterial
expression in one blood sample relative to the other samples, and
investigated the immune response of the hosts to clarify this point.
Our results show a link between GBS gene expression and donor
A immune response, either because donor A immune response
directly influences the bacterial transcriptome, or alternatively,
because both GBS gene expression and immune response in blood
are influenced by a putative pre-diabetic status of donor A.
Further studies are necessary to confirm either hypothesis in
focusing analyses on donors with strictly defined underlying
diseases such as diabetes.
Materials and Methods
Bacterial strain, human blood and growth conditions
The serotype III GBS strain NEM316 used for this study has
been well characterized and its genome has been sequenced [12].
The organism was grown in Todd Hewitt broth supplemented
with 0.2% yeast extract (THY) in 5% CO2 at 37uC until the
OD600 reached 0.75. The bacteria were harvested by centrifuga-
tion for 8 min at 40006ga t3 7 uC, and the cell pellet was
suspended in phosphate-buffered saline (PBS).
Fresh heparinized human blood was obtained from eight
volunteers (4 males and 4 females, arbitrarily named A to H) in
accordance with a protocol approved by the Institutional Review
Board of The Methodist Hospital Research Institute (IRB Protocol
# IRB0108-0005). All donors provided written informed consent
for the collection of samples and subsequent analysis. The donors
were not taking medications that would influence the transcrip-
tome analysis, such as antimicrobial agents. Bacteria were mixed
with 80 ml of whole blood from each donor (final GBS
concentration of ,5610
8 CFU/ml of blood) and incubated at
37uC with slight rotation to avoid sedimentation of blood and
bacterial cells.
Samples for transcriptome analysis were removed immediately
after mixing the bacteria with human blood, and after 30 and
90 min of incubation. Samples for cytokine analysis were removed
before adding the bacteria to the blood and after 90 min of
incubation.
RNA isolation
Bacterial RNA was isolated from each sample as previously
described [13]. The RNA concentration was evaluated by
measuring absorbance at 260 and 280 nm, and RNA quality
was evaluated by electrophoretic analysis with an Agilent 2100
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA).
cDNA synthesis, fragmentation, and labelling
The methods used for cDNA synthesis, fragmentation, and
labelling have been described extensively elsewhere [15].
Expression microarray analysis
Expression microarray analysis was performed with a custom-
made Affymetrix chip formulated based on the genome sequence
of strain NEM316 [12]. The chip contains 1,995 probe sets
corresponding to the annotated open reading frames (ORFs) in
this genome. Briefly, end-labelled cDNA was hybridized overnight
at 40uC using the Affymetrix hybridization and staining modules,
according to the manufacturer’s instructions. Chip hybridization
data were acquired and normalized using Affymetrix GeneChip
Operating Software (GCOS). Hybridization intensity values were
normalized to the mean intensity of all GBS genes present on the
chip using GCOS version 1.0 to permit comparison of data
obtained from multiple experimental conditions. We compared
GBS transcript levels in the donor A blood sample to the average
of transcript levels in the seven other blood samples (donors B to
H) [13].
The microarray data for this study have been deposited in the
Gene Expression Omnibus database (GSE12201 for donor A
blood sample and GSE11705 for donors B to H blood samples).
Cytokine production
The concentration of various cytokines was measured using the
xMAP technology (Luminex Corp., Austin, TX) which combines
the principle of a sandwich immunoassay with fluorescent bead-
based technology. The xMAP serum assay was performed
according to the manufacturer’s instructions for eotaxin, granu-
locyte colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF), interferon-a (IFN-a), inter-
feron-c (IFN-c), interleukin-1a (IL-1a), interleukin-1b (IL-1b),
interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4),
interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7),
interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12p40 (IL-
12p40), interleukin-12p70 (IL-12p70), interleukin-13 (IL-13),
interleukin-15 (IL-15), interleukin-17 (IL-17), interferon-gamma
inducible protein-10 (IP-10), monocyte chemoattractant protein-1
(MCP-1), macrophage inflammatory protein-1a (MIP-1a), mac-
rophage inflammatory protein-1b (MIP-1b), tumor necrosis factor-
Unusual GBS Transcriptome
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inhibitor factor (MIF), and plasminogen activator inhibitor type-
1 (tPAI-1). Experiments were performed in duplicate and samples
were diluted appropriately when necessary.
Bioinformatic analyses
Analyses, statistics, and graphics were performed with Partek
Pro Genomics Suite 6.0 (Partek, St. Louis, MO), ArrayAssist
software v5.5.1 (Stratagene, La Jolla, CA), and GraphPad Prism
v4 (GraphPad Software Inc., San Diego, CA).
Supporting Information
Table S1 Concentration of the cytokines before adding the
bacteria to the blood samples and after 90 min of incubation at
37uC for the eight donors.
Found at: doi:10.1371/journal.pone.0007145.s001 (0.04 MB
PDF)
Table S2 Microarray expression data from GBS strain NEM316
during incubation with human blood at 37uC. GBS transcript
levels in the donor A blood sample were compared to the average
of transcript levels in the seven other blood samples (donors B to
H) after 30 min (Time 1) and 90 min (Time 2) of incubation. Only
ratios greater than 2 and less than 0.5 were considered for analysis,
according to the absent (A), present (P) or marginal (M) level of
transcription in each sample.
Found at: doi:10.1371/journal.pone.0007145.s002 (0.59 MB
PDF)
Acknowledgments
We are indebted to the blood donors for making this study possible. We
also thank Philip D. Randall for editorial help.
Author Contributions
Conceived and designed the experiments: LM IS JMM. Performed the
experiments: LM IS NMG. Analyzed the data: LM IS JMM. Wrote the
paper: LM JMM.
References
1. van der Mee-Marquet N, Fourny L, Arnault L, Domelier AS, Salloum M, et al.
(2008) Molecular characterization of human-colonizing Streptococcus agalactiae
strains isolated from throat, skin, anal margin, and genital body sites. J Clin
Microbiol 46: 2906–2911.
2. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, et al. (2008)
Epidemiology of invasive group B streptococcal disease in the United States,
1999-2005. Jama 299: 2056–2065.
3. Bohnsack JF, Takahashi S, Detrick SR, Pelinka LR, Hammitt LL, et al. (2001)
Phylogenetic classification of serotype III group B streptococci on the basis of
hylB gene analysis and DNA sequences specific to restriction digest pattern type
III-3. J Infect Dis 183: 1694–1697.
4. Hery-Arnaud G, Bruant G, Lanotte P, Brun S, Rosenau A, et al. (2005)
Acquisition of insertion sequences and the GBSi1 intron by Streptococcus agalactiae
isolates correlates with the evolution of the species. J Bacteriol 187: 6248–6252.
5. Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan MS, et al. (2003)
Multilocus sequence typing system for group B streptococcus. J Clin Microbiol
41: 2530–2536.
6. Musser JM, Mattingly SJ, Quentin R, Goudeau A, Selander RK (1989)
Identification of a high-virulence clone of type III Streptococcus agalactiae (group B
streptococcus) causing invasive neonatal disease. Proc Natl Acad Sci U S A 86:
4731–4735.
7. Rolland K, Mereghetti L, Watt S, Chatellier S, Quentin R (2002) tRNA gene
clusters at the 39 end of rRNA operons are specific to virulent subgroups of
Streptococcus agalactiae strains, as demonstrated by molecular differential analysis at
the population level. Microbiology 148: 1493–1499.
8. Bisharat N, Crook DW, Leigh J, Harding RM, Ward PN, et al. (2004)
Hyperinvasive neonatal group B streptococcus has arisen from a bovine
ancestor. J Clin Microbiol 42: 2161–2167.
9. Hery-Arnaud G, Bruant G, Lanotte P, Brun S, Picard B, et al. (2007) Mobile
genetic elements provide evidence for a bovine origin of clonal complex 17 of
Streptococcus agalactiae. Appl Environ Microbiol 73: 4668–4672.
10. Edwards MS, Baker CJ (2005) Group B streptococcal infections in elderly adults.
Clin Infect Dis 41: 839–847.
11. Peleg AY, Weerarathna T, McCarthy JS, Davis TM (2007) Common infections
in diabetes: pathogenesis, management and relationship to glycaemic control.
Diabetes Metab Res Rev 23: 3–13.
12. Glaser P, Rusniok C, Buchrieser C, Chevalier F, Frangeul L, et al. (2002)
Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal
disease. Mol Microbiol 45: 1499–1513.
13. Mereghetti L, Sitkiewicz I, Green NM, Musser JM (2008) Extensive adaptive
changes occur in the transcriptome of Streptococcus agalactiae (group B
streptococcus) in response to incubation with human blood. PLoS ONE 3:
e3143.
14. Herbert MA, Beveridge CJ, McCormick D, Aten E, Jones N, et al. (2005)
Genetic islands of Streptococcus agalactiae strains NEM316 and 2603VR and their
presence in other group B streptococcal strains. BMC Microbiol 5: 31.
15. Mereghetti L, Sitkiewicz I, Green NM, Musser JM (2008) Remodeling of the
Streptococcus agalactiae transcriptome in response to growth temperature. PLoS
ONE 3: e2785.
16. Musser JM, DeLeo FR (2005) Toward a genome-wide systems biology analysis
of host-pathogen interactions in group A streptococcus. Am J Pathol 167:
1461–1472.
17. Virtaneva K, Porcella SF, Graham MR, Ireland RM, Johnson CA, et al. (2005)
Longitudinal analysis of the group A streptococcus transcriptome in experi-
mental pharyngitis in cynomolgus macaques. Proc Natl Acad Sci U S A 102:
9014–9019.
18. Loughman JA, Caparon MG (2006) A novel adaptation of aldolase regulates
virulence in Streptococcus pyogenes. Embo J 25: 5414–5422.
19. Shelburne SA 3rd, Keith D, Horstmann N, Sumby P, Davenport MT, et al.
(2008) A direct link between carbohydrate utilization and virulence in the major
human pathogen group A streptococcus. Proc Natl Acad Sci U S A 105:
1698–1703.
20. Kotb M, Norrby-Teglund A, McGeer A, Green K, Low DE (2003) Association
of human leukocyte antigen with outcomes of infectious diseases: the
streptococcal experience. Scand J Infect Dis 35: 665–669.
21. Liang FT, Yan J, Mbow ML, Sviat SL, Gilmore RD, et al. (2004) Borrelia
burgdorferi changes its surface antigenic expression in response to host immune
responses. Infect Immun 72: 5759–5767.
22. Sendi P, Johansson L, Dahesh S, Van-Sorge NM, Darenberg J, et al. (2009)
Bacterial phenotype variants in group B streptococcal toxic shock syndrome.
Emerg Infect Dis 15: 223–232.
23. Sigge A, Schmid M, Mauerer S, Spellerberg B (2008) Heterogeneity of
hemolysin expression during neonatal Streptococcus agalactiae sepsis. J Clin
Microbiol 46: 807–809.
24. Katial RK, Sachanandani D, Pinney C, Lieberman MM (1998) Cytokine
production in cell culture by peripheral blood mononuclear cells from
immunocompetent hosts. Clin Diagn Lab Immunol 5: 78–81.
25. Wang SM, Lu IH, Lin YL, Lin YS, Wu JJ, et al. (2008) The severity of
Streptococcus pyogenes infections in children is significantly associated with plasma
levels of inflammatory cytokines. Diagn Microbiol Infect Dis 61: 165–169.
26. Alessi MC, Poggi M, Juhan-Vague I (2007) Plasminogen activator inhibitor-1,
adipose tissue and insulin resistance. Curr Opin Lipidol 18: 240–245.
27. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, et al. (2002)
Tissue factor pathway inhibitor and other endothelium-dependent hemostatic
factors in elderly individuals with normal or impaired glucose tolerance and type
2 diabetes. Diabetes Care 25: 1340–1345.
28. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-
phase proteins and plasminogen activator inhibitor-1 predict the development of
type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:
1131–1137.
29. Toso C, Emamaullee JA, Merani S, Shapiro AM (2008) The role of macrophage
migration inhibitory factor on glucose metabolism and diabetes. Diabetologia
51: 1937–1946.
30. Yabunaka N, Nishihira J, Mizue Y, Tsuji M, Kumagai M, et al. (2000) Elevated
serum content of macrophage migration inhibitory factor in patients with type 2
diabetes. Diabetes Care 23: 256–258.
31. Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an
important and previously unrecognized source of macrophage migration
inhibitory factor. J Exp Med 179: 1895–1902.
32. Calandra T (2003) Macrophage migration inhibitory factor and host innate
immune responses to microbes. Scand J Infect Dis 35: 573–576.
33. Kornelisse RF, Hazelzet JA, Savelkoul HF, Hop WC, Suur MH, et al. (1996)
The relationship between plasminogen activator inhibitor-1 and proinflamma-
tory and counterinflammatory mediators in children with meningococcal septic
shock. J Infect Dis 173: 1148–1156.
Unusual GBS Transcriptome
PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e7145